Prediction and prognostic potential of NR3C1 gene expression level in DLBCL patients

References

• Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125:22–32. doi:10.1182/blood-2014-05-577189
   PubMed Web of Science ®Google Scholar
• Havranek O, et al. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. Blood. 2017;130:995–1006. doi:10.1182/blood-2016-10-747303
   PubMed Web of Science ®Google Scholar
• Vardiman JW, et al. The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–951. doi:10.1182/blood-2009-03-209262
   PubMed Web of Science ®Google Scholar
• Wang Y, et al. Late relapses in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2019;37:1819–1827. doi:10.1200/JCO.19.00014
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Dalla-Favera R. Genetics of diffuse large B-cell lymphoma. Blood. 2018;131:2307–2319. doi:10.1182/blood-2017-11-764332
   PubMed Web of Science ®Google Scholar
• Akyurek N, Uner A, Benekli M, et al. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer. 2012;118:4173–4183. doi:10.1002/cncr.27396
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511. doi:10.1038/35000501
   PubMed Web of Science ®Google Scholar
• Hu S, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the international DLBCL rituximab-CHOP consortium program study. Blood. 2013;121:2715–2724. doi:10.1182/blood-2012-10-461848
   PubMed Web of Science ®Google Scholar
• Landsburg DJ, et al. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. Br J Haematol. 2016;175:631–640. doi:10.1111/bjh.14282
   PubMed Web of Science ®Google Scholar
• Encio IJ, Detera-Wadleigh SD. The genomic structure of the human glucocorticoid receptor. J Biol Chem. 1991;266:7182–7188. doi:10.1016/S0021-9258(20)89627-6
   PubMed Web of Science ®Google Scholar
• Lu NZ, Cidlowski JA. Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol Cell. 2005;18:331–342. doi:10.1016/j.molcel.2005.03.025
   PubMed Web of Science ®Google Scholar
• Newton R. Anti-inflammatory glucocorticoids: changing concepts. Eur J Pharmacol. 2014;724:231–236. doi:10.1016/j.ejphar.2013.05.035
   PubMed Web of Science ®Google Scholar
• Lu NZ, Cidlowski JA. The origin and functions of multiple human glucocorticoid receptor isoforms. Ann N Y Acad Sci. 2004;1024:102–123. doi:10.1196/annals.1321.008
   PubMed Web of Science ®Google Scholar
• El-Fayoumi R, Hagras M, Abozenadaha A, et al. Association between NR3C1 gene polymorphisms and toxicity induced by glucocorticoids therapy in Saudi children with acute lymphoblastic leukemia. Asian Pac J Trop. 2018;19:1415–1423.
   Google Scholar
• Emadali A, et al. Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms. Blood. 2016;127:3040–3053. doi:10.1182/blood-2015-09-671040
   PubMed Web of Science ®Google Scholar
• Cardesa-Salzmann TM, et al. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica. 2011;96:996–1001. doi:10.3324/haematol.2010.037408
   PubMed Web of Science ®Google Scholar
• Chen L, et al. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 2013;23:826–838. doi:10.1016/j.ccr.2013.05.002
   PubMed Web of Science ®Google Scholar
• Monti S, et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012;22:359–372. doi:10.1016/j.ccr.2012.07.014
   PubMed Web of Science ®Google Scholar
• Frei E, et al. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. J Clin Pathol. 2013;66:956–961. doi:10.1136/jclinpath-2013-201619
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, et al. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the international DLBCL rituximab-CHOP consortium program. Blood. 2013;122:2630–2640. doi:10.1182/blood-2012-12-473702
   PubMed Web of Science ®Google Scholar
• Aranda CJ, et al. Intestinal epithelial deletion of the glucocorticoid receptor NR3C1 alters expression of inflammatory mediators and barrier function. FASEB J. 2019;33:14067–14082. doi:10.1096/fj.201900404RR
   PubMed Web of Science ®Google Scholar
• Lind GE, et al. ADAMTS1, CRABP1, and NR3C1 were identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell Oncol. 2006;28:259–272.
   PubMed Web of Science ®Google Scholar
• Ahlquist T, et al. Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer. 2008;7(94.
   PubMedGoogle Scholar
• Gu Y, et al. Functional polymorphisms inNR3C1are associated with gastric cancer risk in Chinese population. Oncotarget. 2017;8:105312–105319. doi:10.18632/oncotarget.22172
   PubMedGoogle Scholar
• Tacon LJ, et al. The glucocorticoid receptor is overexpressed in malignant adrenocortical tumors. J Clin Endocrinol Metab. 2009;94:4591–4599. doi:10.1210/jc.2009-0546
   PubMed Web of Science ®Google Scholar
• Pan D, Kocherginsky M, Conzen SD. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res. 2011;71:6360–6370. doi:10.1158/0008-5472.CAN-11-0362
   PubMed Web of Science ®Google Scholar
• Chang W, et al. Identification of novel hub genes associated with liver metastasis of gastric cancer. Int J Cancer. 2009;125:2844–2853. doi:10.1002/ijc.24699
   PubMed Web of Science ®Google Scholar
• Bokemeyer A, et al. Copy number genome alterations are associated with treatment response and outcome in relapsed childhood ETV6/RUNX1-positive acute lymphoblastic leukemia. Haematologica. 2014;99:706–714. doi:10.3324/haematol.2012.072470
   PubMed Web of Science ®Google Scholar
• Irving JA, et al. Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2016;128:911–922. doi:10.1182/blood-2016-03-704973
   PubMed Web of Science ®Google Scholar
• Chan LN, et al. Metabolic gatekeeper function of B-lymphoid transcription factors. Nature. 2017;542:479–483. doi:10.1038/nature21076
   PubMed Web of Science ®Google Scholar
• Al Argan R, Saskin A, Yang JW, et al. Glucocorticoid resistance syndrome caused by a novel <i>NR3C1</i> point mutation. Endocr J. 2018;65:1139–1146. doi:10.1507/endocrj.EJ18-0135
   PubMed Web of Science ®Google Scholar
• Julien S, et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res. 2012;18:5314–5328. doi:10.1158/1078-0432.CCR-12-0372
   PubMed Web of Science ®Google Scholar
• van Rhee F, et al. Total therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood. 2010;116:1220–1227. doi:10.1182/blood-2010-01-264333
   PubMed Web of Science ®Google Scholar